Carmustine medac (previously Carmustine Obvius) European Union - Slovak - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastické činidlá - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Lenalidomid Pharmevid 25 mg Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lenalidomid pharmevid 25 mg

pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata

Lenalidomid Pharmevid 15 mg Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lenalidomid pharmevid 15 mg

pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata

Lenalidomid Pharmevid 10 mg Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lenalidomid pharmevid 10 mg

pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata

Lenalidomid Pharmevid 5 mg Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lenalidomid pharmevid 5 mg

pharmevid s.r.o., slovensko - lenalidomid - 59 - immunopraeparata

Lenalidomid Sandoz 25 mg Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

lenalidomid sandoz 25 mg

sandoz pharmaceuticals d.d., slovinsko - lenalidomid - 59 - immunopraeparata